{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:13:15Z","timestamp":1776262395626,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T00:00:00Z","timestamp":1213056000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00213-007-1064-9","type":"journal-article","created":{"date-parts":[[2008,6,9]],"date-time":"2008-06-09T08:51:39Z","timestamp":1213001499000},"page":"15-27","source":"Crossref","is-referenced-by-count":29,"title":["Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of \u03b11-adrenoceptor function"],"prefix":"10.1007","volume":"199","author":[{"given":"Z.","family":"Nourian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Mow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Muftic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Burek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Matz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Mulvany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,10]]},"reference":[{"key":"1064_CR1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1254\/jjp.90.131","volume":"90","author":"K Akiyama","year":"2002","unstructured":"Akiyama K, Hora M, Yamagishi R, Kitazawa M (2002) Effects of KMD-3213, a uroselective alpha 1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats. Jpn J Pharmacol 90:131\u2013137","journal-title":"Jpn J Pharmacol"},{"key":"1064_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s002280050067","volume":"50","author":"E Andros","year":"1996","unstructured":"Andros E, Detmar-Hanna D, Suteparuk S, Gal J, Gerber JG (1996) The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Eur J Clin Pharmacol 50:41\u201346","journal-title":"Eur J Clin Pharmacol"},{"key":"1064_CR3","first-page":"48","volume":"14","author":"O Arunlakshano","year":"1959","unstructured":"Arunlakshano O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48\u201358","journal-title":"Br J Pharmacol"},{"key":"1064_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1192\/S0007125000298097","volume":"38","author":"TR Barnes","year":"1999","unstructured":"Barnes TR, McPhillips MA (1999) Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl 38:34\u201343","journal-title":"Br J Psychiatry Suppl"},{"key":"1064_CR5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0924-977X(96)00392-6","volume":"7","author":"CM Beasley Jr.","year":"1997","unstructured":"Beasley CM Jr., Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN (1997) Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7:125\u2013137","journal-title":"Eur Neuropsychopharmacol"},{"key":"1064_CR6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00002018-200023030-00004","volume":"23","author":"NA Buckley","year":"2000","unstructured":"Buckley NA, Sanders P (2000) Cardiovascular adverse effects of antipsychotic drugs. Drug Safety 23:215\u2013228","journal-title":"Drug Safety"},{"key":"1064_CR7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381\u2013389","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 11","key":"1064_CR8","first-page":"40","volume":"57","author":"DE Casey","year":"1996","unstructured":"Casey DE (1996) Side effect profiles of new antipsychotic agents. J Clin Psychiatry 57(Suppl 11):40\u201345","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 10","key":"1064_CR9","first-page":"55","volume":"58","author":"DE Casey","year":"1997","unstructured":"Casey DE (1997) The relationship of pharmacology to side effects. J Clin Psychiatry 58(Suppl 10):55\u201362","journal-title":"J Clin Psychiatry"},{"key":"1064_CR10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1152\/physiolgenomics.00065.2001","volume":"9","author":"CJ Daly","year":"2002","unstructured":"Daly CJ, Deighan C, McGee A, Mennie D, Ali Z, McBride M, McGrath JC (2002) A knockout approach indicates a minor vasoconstrictor role for vascular alpha1B-adrenoceptors in mouse. Physiol Genomics 9:85\u201391","journal-title":"Physiol Genomics"},{"key":"1064_CR11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.bjp.0706039","volume":"144","author":"MM Moura de","year":"2005","unstructured":"de Moura MM, dos Santos RA, Fontes MA (2005) Evidence for a functional cardiac interaction between losartan and angiotensin-(1\u20137) receptors revealed by orthostatic tilting test in rats. Br J Pharmacol 144:755\u2013760","journal-title":"Br J Pharmacol"},{"key":"1064_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(98)00682-7","volume":"361","author":"JR Docherty","year":"1998","unstructured":"Docherty JR (1998) Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J Pharmacol 361:1\u201315","journal-title":"Eur J Pharmacol"},{"key":"1064_CR13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0014-2999(95)00685-0","volume":"295","author":"M Eltze","year":"1996","unstructured":"Eltze M (1996) In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol 295:69\u201373","journal-title":"Eur J Pharmacol"},{"issue":"Pt 3","key":"1064_CR14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1113\/jphysiol.1995.sp021006","volume":"488","author":"J Fenger-Gron","year":"1995","unstructured":"Fenger-Gron J, Mulvany MJ, Christensen KL (1995) Mesenteric blood pressure profile of conscious, freely moving rats. J Physiol 488(Pt 3):753\u2013760","journal-title":"J Physiol"},{"key":"1064_CR15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.bjp.0705033","volume":"138","author":"R Gisbert","year":"2003","unstructured":"Gisbert R, Madrero Y, Sabino V, Noguera MA, Ivorra MD, D\u2019Ocon P (2003) Functional characterization of alpha 1-adrenoceptor subtypes in vascular tissues using different experimental approaches: a comparative study. Br J Pharmacol 138:359\u2013368","journal-title":"Br J Pharmacol"},{"key":"1064_CR16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1254\/jjp.81.63","volume":"81","author":"Y Hashimoto","year":"1999","unstructured":"Hashimoto Y, Ohashi R, Minami K, Narita H (1999) Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension. Jpn J Pharmacol 81:63\u201372","journal-title":"Jpn J Pharmacol"},{"key":"1064_CR17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(99)00227-7","volume":"373","author":"JP Hieble","year":"1999","unstructured":"Hieble JP, Kolpak DC, McCafferty GP, Ruffolo RR Jr., Testa R, Leonardi A (1999) Effects of alpha1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: relationships to uroselectivity. Eur J Pharmacol 373:51\u201362","journal-title":"Eur J Pharmacol"},{"key":"1064_CR18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0022-3565(24)34920-1","volume":"290","author":"SL Hrometz","year":"1999","unstructured":"Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM, Piascik MT (1999) Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction. J Pharmacol Exp Ther 290:452\u2013463","journal-title":"J Pharmacol Exp Ther"},{"key":"1064_CR19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.bjp.0701461","volume":"122","author":"MB Hussain","year":"1997","unstructured":"Hussain MB, Marshall I (1997) Characterization of alpha1-adrenoceptor subtypes mediating contractions to phenylephrine in rat thoracic aorta, mesenteric artery and pulmonary artery. Br J Pharmacol 122:849\u2013858","journal-title":"Br J Pharmacol"},{"key":"1064_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-2999(97)01242-9","volume":"336","author":"M Ipsen","year":"1997","unstructured":"Ipsen M, Zhang Y, Dragsted N, Han C, Mulvany MJ (1997) The antipsychotic drug sertindole is a specific inhibitor of alpha1A-adrenoceptors in rat mesenteric small arteries. Eur J Pharmacol 336:29\u201335","journal-title":"Eur J Pharmacol"},{"key":"1064_CR21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137\u2013140","journal-title":"Eur J Pharmacol"},{"key":"1064_CR22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/13543784.12.4.655","volume":"12","author":"PE Keck Jr.","year":"2003","unstructured":"Keck PE Jr., McElroy SL (2003) Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 12:655\u2013662","journal-title":"Expert Opin Investig Drugs"},{"key":"1064_CR23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1476-5381.1995.tb15907.x","volume":"115","author":"BA Kenny","year":"1995","unstructured":"Kenny BA, Chalmers DH, Philpott PC, Naylor AM (1995) Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol 115:981\u2013986","journal-title":"Br J Pharmacol"},{"key":"1064_CR24","first-page":"305","volume":"23","author":"LC Kopala","year":"1998","unstructured":"Kopala LC, Day C, Dillman B, Gardner D (1998) A case of risperidone overdose in early schizophrenia: a review of potential complications. J Psychiatry Neurosci. 23:305\u2013308","journal-title":"J Psychiatry Neurosci."},{"key":"1064_CR25","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archneur.57.10.1461","volume":"57","author":"K Kujawa","year":"2000","unstructured":"Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG (2000) Acute orthostatic hypotension when starting dopamine agonists in Parkinson\u2019s disease. Arch Neurol 57:1461\u20131463","journal-title":"Arch Neurol"},{"key":"1064_CR26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0006-8993(88)90390-3","volume":"460","author":"RF Lane","year":"1988","unstructured":"Lane RF, Blaha CD, Rivet JM (1988) Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: involvement of alpha 1-noradrenergic receptors demonstrated by in vivo voltammetry. Brain Res 460:398\u2013401","journal-title":"Brain Res"},{"key":"1064_CR27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1017\/S0317167100030997","volume":"17","author":"AE Lang","year":"1990","unstructured":"Lang AE, Riley DE, Vachon L, Lataste X (1990) CQA 206\u2013291 in Parkinson\u2019s disease: an acute single escalating dosage study. Can J Neurol Sci 17:416\u2013419","journal-title":"Can J Neurol Sci"},{"key":"1064_CR28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0896-6273(00)00111-2","volume":"28","author":"DA Lewis","year":"2000","unstructured":"Lewis DA, Lieberman JA (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325\u2013334","journal-title":"Neuron"},{"key":"1064_CR29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0165-6147(98)01186-9","volume":"19","author":"MS Lidow","year":"1998","unstructured":"Lidow MS, Williams GV, Goldman-Rakic PS (1998) The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 19:136\u2013140","journal-title":"Trends Pharmacol Sci"},{"key":"1064_CR30","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/clpt.1988.210","volume":"44","author":"dF Lopes Sr.","year":"1988","unstructured":"Lopes dF Sr., Zanella MT, Andriolo A, Ribeiro AB, Chacra AR (1988) Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. Clin Pharmacol Ther 44:670\u2013674","journal-title":"Clin Pharmacol Ther"},{"key":"1064_CR31","doi-asserted-by":"crossref","first-page":"H1923","DOI":"10.1152\/ajpheart.00288.2005","volume":"289","author":"D Marti","year":"2005","unstructured":"Marti D, Miquel R, Ziani K, Gisbert R, Ivorra MD, Anselmi E, Moreno L, Villagrasa V, Barettino D, D\u2019Ocon P (2005) Correlation between mRNA levels and functional role of alpha1-adrenoceptor subtypes in arteries: evidence of alpha1L as a functional isoform of the alpha1A-adrenoceptor. Am J Physiol Heart Circ Physiol 289:H1923\u2013H1932","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1064_CR32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.RES.41.1.19","volume":"41","author":"MJ Mulvany","year":"1977","unstructured":"Mulvany MJ, Halpern W (1977) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41:19\u201326","journal-title":"Circ Res"},{"key":"1064_CR33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-3565(24)29397-6","volume":"298","author":"MT Piascik","year":"2001","unstructured":"Piascik MT, Perez DM (2001) Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 298:403\u2013410","journal-title":"J Pharmacol Exp Ther"},{"key":"1064_CR34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2710.2005.00629.x","volume":"30","author":"IO Poon","year":"2005","unstructured":"Poon IO, Braun U (2005) High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 30:173\u2013178","journal-title":"J Clin Pharm Ther"},{"key":"1064_CR35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-2999(94)90041-8","volume":"262","author":"EP Prinssen","year":"1994","unstructured":"Prinssen EP, Ellenbroek BA, Cools AR (1994) Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262:167\u2013170","journal-title":"Eur J Pharmacol"},{"key":"1064_CR36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29\u201339","journal-title":"Life Sci"},{"key":"1064_CR37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pbb.2003.12.001","volume":"77","author":"C Sanchez","year":"2004","unstructured":"Sanchez C, Kreilgaard M (2004) R-Citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77:391\u2013398","journal-title":"Pharmacol Biochem Behav"},{"key":"1064_CR38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","volume":"425","author":"AW Schmidt","year":"2001","unstructured":"Schmidt AW, Lebel LA, Howard HR Jr., Zorn SH (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425:197\u2013201","journal-title":"Eur J Pharmacol"},{"key":"1064_CR39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W, Luyten WH, Van GP, Lesage AS, De LK, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57\u201373","journal-title":"Psychopharmacology (Berl)"},{"key":"1064_CR40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1034\/j.1600-0404.2001.104002092.x","volume":"104","author":"GR Sigurdardottir","year":"2001","unstructured":"Sigurdardottir GR, Nilsson C, Odin P, Grabowski M (2001) Cardiovascular effects of domperidone in patients with Parkinson\u2019s disease treated with apomorphine. Acta Neurol Scand 104:92\u201396","journal-title":"Acta Neurol Scand"},{"key":"1064_CR41","first-page":"459","volume":"51","author":"H Silver","year":"1990","unstructured":"Silver H, Kogan H, Zlotogorski D (1990) Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 51:459\u2013462","journal-title":"J Clin Psychiatry"},{"key":"1064_CR42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0014-2999(93)90876-J","volume":"238","author":"AJ Sleight","year":"1993","unstructured":"Sleight AJ, Koek W, Bigg DC (1993) Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol 238:407\u2013410","journal-title":"Eur J Pharmacol"},{"key":"1064_CR43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004714-199710000-00011","volume":"17","author":"JJ Sramek","year":"1997","unstructured":"Sramek JJ, Mack RJ, Awni W, Hourani J, Jhee SS, Barto S, Cutler NR (1997) Two rapid-dose titrations of sertindole in patients with schizophrenia. J Clin Psychopharmacol 17:419\u2013422","journal-title":"J Clin Psychopharmacol"},{"key":"1064_CR44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/sj.bjp.0702598","volume":"127","author":"WB Stam","year":"1999","unstructured":"Stam WB, Van der Graaf PH, Saxena PR (1999) Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery. Br J Pharmacol 127:661\u2013670","journal-title":"Br J Pharmacol"},{"key":"1064_CR45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002018-200022030-00004","volume":"22","author":"C Stanniland","year":"2000","unstructured":"Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Safety 22:195\u2013214","journal-title":"Drug Safety"},{"key":"1064_CR46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0031-6997(24)01483-2","volume":"53","author":"PG Strange","year":"2001","unstructured":"Strange PG (2001) Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53:119\u2013133","journal-title":"Pharmacol Rev"},{"key":"1064_CR47","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","volume":"27","author":"TH Svensson","year":"2003","unstructured":"Svensson TH (2003) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1145\u20131158","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1064_CR48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1254\/jjp.77.61","volume":"77","author":"H Take","year":"1998","unstructured":"Take H, Shibata K, Awaji T, Hirasawa A, Ikegaki I, Asano T, Takada T, Tsujimoto G (1998) Vascular alpha1-adrenoceptor subtype selectivity and alpha1-blocker-induced orthostatic hypotension. Jpn J Pharmacol 77:61\u201370","journal-title":"Jpn J Pharmacol"},{"key":"1064_CR49","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0022-3565(24)36702-3","volume":"281","author":"R Testa","year":"1997","unstructured":"Testa R, Guarneri L, Angelico P, Poggesi E, Taddei C, Sironi G, Colombo D, Sulpizio AC, Naselsky DP, Hieble JP, Leonardi A (1997) Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15\/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. J Pharmacol Exp Ther 281:1284\u20131293","journal-title":"J Pharmacol Exp Ther"},{"key":"1064_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(01)00212-2","volume":"56","author":"A Tuunainen","year":"2002","unstructured":"Tuunainen A, Wahlbeck K, Gilbody S (2002) Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 56:1\u201310","journal-title":"Schizophr Res"},{"key":"1064_CR51","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s007020070036","volume":"107","author":"ML Wadenberg","year":"2000","unstructured":"Wadenberg ML, Hertel P, Fernholm R, Hygge BK, Ahlenius S, Svensson TH (2000) Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J Neural Transm 107:1229\u20131238","journal-title":"J Neural Transm"},{"key":"1064_CR52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2004.01.013","volume":"71","author":"JB Williams","year":"2004","unstructured":"Williams JB, Mallorga PJ, Jeffrey CP, Pettibone DJ, Sur C (2004) Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res 71:103\u2013112","journal-title":"Schizophr Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-1064-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-007-1064-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-1064-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:10:27Z","timestamp":1738257027000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-007-1064-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,10]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["1064"],"URL":"https:\/\/doi.org\/10.1007\/s00213-007-1064-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,10]]}}}